Forest Labs profit plunges as Lexapro loses patent

18 April 2012

US drugmaker Forest Laboratories (NYSE: FRX) that reported earnings per share equaled $0.72 in the fourth quarter of fiscal 2012, down a sharp 36% from $1.12 in the like, year-earlier quarter. Excluding acquisition related amortization, non-GAAP EPS in the fourth fiscal quarter of 2012 equaled $0.78 as compared with $1.14 in the fourth quarter of fiscal 2011.

Revenues fell 7.3% to $1.06 billion from the year-earlier quarter, impacted by the arrival of generic versions of its best-selling anti-depressant Lexapro (escitalopram), which came to market during the reporting quarter.

Notwithstanding, Forest’s share rose 2.8% to $34.60 in morning trading yesterday, as analysts had anticipated the downturn due to Lexapro. Analysts polled by FactSet Research had expected the firm to earn $0.70 a share on revenue of $1.02 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical